Business Daily from THE HINDU group of publications
Tuesday, May 06, 2008
ePaper | Mobile/PDA Version | Audio
News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

 Corporate - IPR
Suven Life gets European patent

Hyderabad, May 5

Suven Life Sciences Ltd secured a product patent for its clinical candidate being developed for the central nervous system (CNS) disorders in the treatment of cognitive impairment from the European Patent Office (EPO). The patent (EP 1581492) has been granted to SUVN-502 which is valid until June 2023. `Granting of this patent to our clinical candidate is more timely and relevant now that the candidate is entering into clinical trials,'' Mr Venkat Jasti, Chief Executive Officer, Suven Life Sciences said in a release. - Our Bureau

More Stories on : IPR | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Work resumes at Hero Honda plant

Kesoram Ind to pay 55%
Govt may retain powers to exempt LLP firms from audit requirements
Suven Life gets European patent
Geojit to exit commodity business to clear hurdles for BNP takeover
Serum Institute picks up 1% stake in Orchid Chem
Stage set for BHEL’s takeover of BHPV
Kesoram plans to raise tyre output capacity at Uttarakhand unit
Siemens may set up facility in AP
Videocon, Hansen among proposals okayed by TN
India Inc will continue overseas M&A ride: Kamath
Patel’s move to expand overseas
IFFCO to form joint venture in Australia
GSK in pact with Japanese co
Volvo Car ties up with Mondial
NDTV Imagine to enter movie production
Sesa Goa moves to increase third party mining
JSW Steel scouting for more mines
Murugappa group plans Rs 1,300-cr capital spend


Smartbuy
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line